Molecular Partners AG
MOLNHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeMolecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Valued at $166.6M, MOLN is a micro-cap name in its sector. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Market Cap
$166.6M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-25.91
EPS (TTM)
$-1.66
EPS (Fwd)
$-0.17
ROE
-62.0%
ROA
-32.3%
Cash
$67.9M
Total Debt
$3.0M
Free CF
-$27.0M
52W Change
21.5%
Annual Financials
Cash vs Debt
Where MOLN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MOLN finished 4.01% below its 150-day moving average ($4.24) and 4.01% below its 200-day moving average ($4.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MOLN overbought or oversold?
At the September 3, 2026 close, MOLN's RSI(14) was 44.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Molecular Partners AG holds $67.9M in cash against $3.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$27.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -62.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $189.6M (2022) to $0 (2025), a 100% decline worth watching.
MOLN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, MOLN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Molecular Partners AG's trajectory.